Background: Glia-neuron interactions play an important role in the development of neuropathic pain. Expression of the pro-inflammatory cytokne !cytokine Interferon-gamma (IFNg) is upregulated in the dorsal horn after peripheral nerve injury, and intrathecal IFNg administration induces mechanical allodynia in rats. A growing body of evidence suggests that IFNg might be involved in the mechanisms of neuropathic pain, but its effects on the spinal dorsal horn are unclear. We performed blind whole-cell patch-clamp recording to investigate the effect of IFNg on postsynaptic glutamate-induced currents in the substantia gelatinosa neurons of spinal cord slices from adult male rats. Results: IFNg perfusion significantly enhanced the amplitude of NMDA-induced inward currents in substantia gelatinosa neurons, but did not affect AMPA-induced currents. The facilitation of NMDA-induced current by IFNg was inhibited by bath application of an IFNg receptor-selective antagonist. Adding the Janus activated kinase inhibitor tofacitinib to the pipette solution did not affect the IFNg-induced facilitation of NMDA-induced currents. However, the facilitatory effect of IFNg on NMDA-induced currents was inhibited by perfusion of the microglial inhibitor minocycline. These results suggest that IFNg binds the microglial IFNg receptor and enhances NMDA receptor activity in substantia gelatinosa neurons. Next, to identify the effector of signal transmission from microglia to dorsal horn neurons, we added an inhibitor of G proteins, GDP-b-S, to the pipette solution. In a GDP-b-S-containing pipette solution, IFNg-induced potentiation of the NMDA current was significantly suppressed after 30 min. In addition, IFNg-induced potentiation of NMDA currents was blocked by application of a selective antagonist of CCR2, and its ligand CCL2 increased NMDA-induced currents. Conclusion: Our findings suggest that IFNg enhance the amplitude of NMDA-induced inward currents in substantia gelatinosa neurons via microglial IFNg receptors and CCL2/CCR2 signaling. This mechanism might be partially responsible for the development of persistent neuropathic pain.
Background
Patients with neuropathic pain experience spontaneous tingling sensations, hyperalgesia, and tactile allodynia, symptoms that deteriorate their quality of life. The pathogenesis of neuropathic pain is believed to involve central sensitization of spinal dorsal horn neurons following central or peripheral nervous system damage. [1] [2] [3] It was recently suggested that neuron-glia interactions play a crucial role in the development of central sensitization. 4, 5 Various cytokines or chemokines have been reported to be involved in facilitating neuron-glia crosstalk. [6] [7] [8] Interferon-gamma (IFNg) is a pro-inflammatory cytokine and a major modulator of central and peripheral immune responses 9 that plays roles in a variety of chronic pain conditions. For example, patients with persistent pain due to viral infections or multiple sclerosis have persistently high IFNg levels in the spinal cord as an inflammatory response. 10, 11 This cytokine is produced primarily by T-cells and natural killer cells 12 and stimulates the Janus activated kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. 13, 14 Upon peripheral nerve injury, IFNg is upregulated in the rat dorsal horn as T-cells that infiltrate the spinal cord, and it has been implicated as one of the causative agents of neuropathic pain. [15] [16] [17] Interestingly, intrathecal injections of IFNg induce painrelated behaviors in wildtype rats and mice but not IFNg receptor knock-out mice. [18] [19] [20] [21] However, little is known about the roles of IFNg in the dorsal horn of the spinal cord.
The substantia gelatinosa (SG, lamina II) of the spinal cord dorsal horn has been implicated in nociceptive transmission because both finely myelinated (Ad) and unmyelinated (C) primary nociceptive afferent fibers are heavily projected to this spinal region. [22] [23] [24] To elucidate how IFNg affects nociceptive responses in the spinal dorsal horn, we analyzed the effects of IFNg on postsynaptic action by using whole-cell patch-clamp recordings from SG neurons.
Methods
Five to six-week-old male Sprague Dawley rats (180-210 g; obtained from SLC, Japan) were used. The protocol was approved by the Ethics Committee on Animal Experiments, Wakayama Medical University, and was in accordance with the UK Animals (Scientific Procedures) Act of 1986 and associated guidelines. Animals were housed in plastic cages at room temperature on a 12-h light/dark cycle (light on between 8:00 a.m. and 8:00 p.m.) with ad libitum access to food and water.
Spinal cord slice preparation L4-5 level transverse spinal cord slices were prepared, as described previously. 25 Briefly, the adult rats were anesthetized with urethane (1.2 g/kg, intraperitoneal), and Th10-L4 laminectomy was performed. Then, we excised the spinal cord and submerged it in preoxygenated Krebs' solution at 1-3 C. Immediately after the removal of the spinal cord, the rats were killed by exsanguination under urethane. The dura, arachnoid, and pia mater were removed, and the spinal segment was sliced to 650-mm thickness by using a microslicer (DTK-1000, Dousaka from Kyoto, Japan). The slices were continuously perfused with Krebs' solution (10 ml/min) and saturated with 95% O 2 and 5% CO 2 . The perfusion solution was heated to 36 AE 1 C by using a temperature controller. The Krebs' solution contained the following (in mM): 117 NaCl, 3. CA, USA) in voltage-clamp mode. Holding potential was set to À70 mV for recording exogenous a-amino-3-hydroxy-5-methyl-4-Isoxazole-4-propionic acid (AMPA) current and to À50 mV for N-methyl-D-aspartate (NMDA) current. Data were digitized using an analogto-digital converter (Digidata 1440A from Molecular Devices), stored, and then analyzed using a personal computer with the pCLAMP 10 data acquisition program (Molecular Devices).
Drug application
The drugs used in this study were IFNg (PeproTech, Rocky Hill, NJ, USA); IFNg antagonist (VWR International, Radnor, PA, USA); monocyte chemoattractant protein 1 (MCP-1) (R&D, Minneapolis, MN, USA); and, AMPA, NMDA, minocycline hydrochloride, Teijin compound 1 hydrochloride, GDP-b-S, and tofacitinib citrate (Sigma-Aldrich, St. Louis, MO, USA). IFNg antagonist, MCP-1, AMPA, NMDA, and minocycline hydrochloride were dissolved in distilled water as 1,000 Â stock solutions, and Teijin compound 1 hydrochloride and tofacitinib citrate 26 were first dissolved in 5% DMSO as 1,000 Â stock solutions. The 1,000 Â stock solutions of IFNg were prepared in distilled water containing 1% bovine serum albumin (BSA) (Sigma-Aldrich). All perfusion drugs were stored at À20 C and diluted to the final concentration in Krebs solution just before use, and then were perfused via a three-way stopcock without any change in the rate or temperature. The time necessary for the solution to flow from the stopcock to the spinal cord section surface was about 1 min. GDP-b-S and tofacitinib citrate were added to the pipette solution. The tubing of our perfusion system was coated with AquaSil siliconizing fluid (Thermo Fisher Scientific, Waltham, MA, USA) to reduce the loss of IFNg through nonspecific interactions.
Statistical analysis
All numerical data are expressed as mean AE standard error (SE). Paired Student's t tests were used for statistical comparison, and the criterion for statistical significance was p < 0.05; n refers to the number of neurons studied.
Results

IFN enhanced NMDA-induced but not AMPA-induced inward currents
Only SG neurons, with resting membrane potentials lower than À50 mV in the current-clamp mode, were used for recording. Perfusion of exogenous AMPA (10 mM) for 30 s onto the spinal cord slice induces slow inward currents at a holding potential of À70 mV, and NMDA (50 mM) does so at À50 mV. This discrepancy is because NMDA receptors are blocked by Mg 2þ when the cell membrane is held at À70 mV. AMPA superfusion repeatedly produces an inward current with the same peak amplitude in an SG neuron (101.3 AE 0.6%, n ¼ 5, p ¼ 0.09), observed for NMDA (97.9 AE 3.1%, n ¼ 5, p ¼ 0.53). We first examined the effects of IFNg on inward currents induced by AMPA and NMDA when maintaining the voltage at À70 and À50 mV, respectively. Bath application of IFNg (30 nM, 2.5 min) did not affect the AMPA-induced current (100.0 AE3.7%, n ¼ 11, p ¼ 0.87, mean amplitude of control: 51.5 pA; Figure 1(a),(c) ). On the other hand, NMDA-induced current was significantly increased by IFNg (147.3 AE 10.7%, n ¼ 14, p ¼ 0.0002, mean amplitude of control: 16.8 pA; Figure 1(b),(d) ). This IFNg-induced facilitation of NMDA current was inhibited by an IFNg receptor-selective antagonist (300 nM, 5.5 min) (90.0 AE 3.6%, n ¼ 10, p ¼ 0.053; Figure 2 ). These results suggest that IFNg binds to own receptor and enhances the activity of NMDA but not AMPA receptors in the dorsal horn of the spinal cord.
Potentiation of NMDA-induced currents by IFN was mediated by glial activation
Because both neurons and microglia are reported as sites of IFNg receptors, 20, 27 we investigated which receptor is responsible for the IFNg-induced potentiation of NMDA-induced currents. As shown in Figure 3 , the IFNg-induced facilitation of NMDA currents was inhibited by minocycline (20 mM, 5.5 min), an inhibitor of microglia activation (90.3 AE 6.4%, n ¼ 12, p ¼ 0.12). In addition, we recorded the IFNg-induced facilitation of NMDA current during inhibition of JAK-STAT signaling. We added the JAK inhibitor tofacitinib (1 mM) to the pipette solution. Despite blocking JAK-STAT signaling, IFNg-induced facilitation of NMDA currents was not affected even after 30 min (98.9 AE 6.0%, n ¼ 7, p ¼ 0.99; Figure 4) . Therefore, we considered that IFNg activates the microglial IFNg receptor and enhances the activity of NMDA receptors in the dorsal horn neuron.
CCL2 is involved in IFN-induced activation of NMDA receptors
As JAK-STAT signaling was not the intraneuronal signal transducer underlying the effect of IFNg on NMDA currents, we examined another possible signaling pathway. First, we added 1 mM GDP-b-S, a nonhydrolysable analog of GDP that competitively inhibits G proteins, to the pipette solution. NMDA-induced inward currents were significantly suppressed when IFNg and NMDA were applied 30 min after patch clamping with pipettes containing GDP-b-S (78.7 AE 5.1%, n ¼ 6, p ¼ 0.023; Figure 5 ). These findings suggested that the IFNg-induced increase of NMDA currents involves the activation of G protein-coupled receptors such as chemokine receptors. Specifically, the chemokine MCP-1, also known as chemokine ligand 2, CCL2 and its receptor C-C chemokine receptor type 2 (CCR2) are reportedly involved in the generation of neuropathic pain 4, 5, 7, 28 and are related to IFNg. 9, 29 We then investigated the participation of CCL2/CCR2 in this effect of IFNg on NMDA currents. IFNg-induced enhancement of NMDA currents was blocked by a selective antagonist of CCR2, Teijin compound 1 hydrochloride (10 mM, 5.5 min) (95.0 AE 5.3%, n ¼ 6, p ¼ 0.43; Figure 6 ). In addition, bath-applied CCL2 (100 ng/ml) for 2.5 min enhanced NMDA-induced inward current (128.3 AE 6.4%, n ¼ 5, p ¼ 0.006; Figure 7 ). Therefore, it is possible that microglia activated by IFNg release CCL2, which binds to CCR2 and enhances neuronal NMDA-induced current.
Discussion
In the present study, IFNg significantly enhanced NMDA-induced inward currents but not AMPAinduced inward currents in SG neurons. This IFNg-induced facilitation of NMDA current was inhibited by an IFNg receptor-selective antagonist. The results suggest that IFNg enhances NMDA receptor signaling by activating IFNg receptors in the dorsal horn of the spinal cord. Minocycline, an inhibitor of microglial activation, inhibited the IFNg-induced facilitation of NMDA current, but inhibition of the neuronal JAK-STAT signaling did not. Therefore, we conclude that IFNg binds its own receptors in microglia but not SG neurons, and the subsequent microglial activation leads to NMDA receptor activation. Moreover, IFNg-induced enhancement of NMDA currents was blocked by GDP-b-S in the pipette solution or bath application of a CCR2 antagonist. CCR2 signaling is mediated by a G protein and a typical chemokine involved in central sensitization. Application of CCL2 alone also enhanced NMDA-induced current. These results suggested that activation of IFNg receptors in the spinal microglia leads to CCL2 release and subsequently enhances NMDA receptors in dorsal horn neurons (Figure 8) .
Importantly, this is the first study to investigate the function of IFNg using blind whole-cell patch-clamp methods. Interestingly, inward currents induced by exogenously applied NMDA, but not AMPA, were clearly enhanced by the application of IFNg in SG neurons of adult rat spinal cord slices. This postsynaptic effect of IFNg on NMDA receptor could explain the pain-related behaviors caused by intrathecal IFNg. [19] [20] [21] In fact, there is considerable evidence that chronic pain hypersensitivity depends on NMDA receptors. [30] [31] [32] [33] It is commonly known that NMDA receptor activation is an essential step in initiating and maintaining activitydependent central sensitization, and it critically contributes to the development of pain hypersensitivity after peripheral tissue damage or nerve injury. 3, 30, 31, 33 On the other hand, no acute changes in AMPA-induced current were observed after superfusing IFNg into the SG neurons of rat spinal cord slices.
Tsuda et al. clearly demonstrated that the IFNg/IFNg receptor system is critical in activating resting spinal microglia, thereby linking them to tactile allodynia. They indicated that spinal microglia are directly stimulated by intrathecal IFNg and contribute to IFNg receptor-dependent pain hypersensitivity. 20 Our findings also showed that IFNg-induced enhancement of NMDA currents was microglial IFNg receptor-dependent. The present results are strongly supported by those of a previous study. 20 Notably, CCR2 blockade inhibited the IFNg-induced enhancement of NMDA-induced inward currents and CCL2 increases NMDA current in SG neurons. Gao et al. 34 demonstrated electrophysiologically that CCL2 can very rapidly (within 2 min) increase NMDA currents in dorsal horn neurons. 34 They showed that incubation of the mouse spinal cord slices with 100 ng/ml CCL2 induced substantial activation of extracellular regulated kinase (ERK) in lamina I-II, and ERK phosphorylation was primarily induced in NeuN-positive neurons, indicating that CCL2 may directly act on neurons. CCL2/ CCR2 signaling plays a crucial role in processing neuropathic pain. [35] [36] [37] For instance, exogenous spinal administration of CCL2 induces mechanical allodynia in wildtype but not CCR2 knockout mice, 37 and in a model of neuropathic pain the development of mechanical allodynia is totally abrogated in CCR2 knockout mice. 38 These results are consistent with ours, and in addition, we found that CCL2 lies downstream of IFNg in terms of NMDA-induced currents.
Conclusions
In summary, our results show that IFNg enhanced NMDA-induced inward currents in SG neurons through the activation of IFNg receptors in microglia, and CCL2 was one of the mediators between microglia and neurons. Thus, IFNg plays an important role as one of the initiating agents of glia-neuron interactions that lead to neuropathic pain due to central sensitization.
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